Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FHIT | P49789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870324 | 1.00 | GBA1 (0.39) | GBA1MAOAMAOBPDE4BMAPK1 | |
| SCHEMBL6866064 | 0.88 | GBA1 (0.38) | GBA1MAOAMAOBMAPK1HSD17B10 | |
| SCHEMBL6866066 | 0.88 | GBA1 (0.38) | GBA1MAOAMAOBMAPK1HSD17B10 | |
| SCHEMBL6867776 | 0.87 | GBA1 (0.44) | GBA1MAOAMAOBPDE4BMAPK1 | |
| SCHEMBL7794175 | 0.85 | GBA1 (0.42) | GBA1MAOAMAOBPDE4BMAPK1 | |
| SCHEMBL6864871 | 0.85 | ALDH1A1 (0.39) | MAOAMAOBPDE4BMAPK1HSD17B10 | |
| SCHEMBL6864866 | 0.85 | ALDH1A1 (0.39) | MAOAMAOBPDE4BMAPK1HSD17B10 | |
| SCHEMBL7613510 | 0.84 | KDM4E (0.39) | GBA1MAOAMAOBMAPK1HSD17B10 | |
| SCHEMBL7613513 | 0.84 | KDM4E (0.39) | GBA1MAOAMAOBMAPK1HSD17B10 | |
| SCHEMBL7075879 | 0.83 | LMNA (0.41) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812331-B2 | BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | AVENTIS PHARMA S.A. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | RPIA, CD38, PARP1 | GBA1 578/4885MAOA 1017/4885MAOB 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.